Exozymes (EXOZ) Share-based Compensation (2023 - 2026)
Exozymes (EXOZ) posted quarterly Share-based Compensation of $677866.0 for Q4 2025, up 113.65% year-over-year from $317277.0 in Q4 2024, and down 77.94% quarter-over-quarter from $3.1 million in Q3 2025.
Exozymes (EXOZ) Share-based Compensation (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Share-based Compensation for 3 consecutive years, with $677866.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation rose 113.65% year-over-year to $677866.0; the TTM figure through Dec 2025 stood at $1.6 million (up 69.99% YoY), while the FY2025 annual figure was $2.7 million, down 40.05% from the prior year.
- Share-based Compensation eased to $677866.0 in Q4 2025 per EXOZ's latest filing, from $3.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.9 million in Q3 2024 and bottomed at $61363.0 in Q3 2023.
- Historically, Share-based Compensation has averaged $1.0 million across 3 years, with a median of $317277.0 in 2024.
- Annual changes were most pronounced in 2024 — Share-based Compensation soared 7838.98% — and 2025, when it slumped 36.91%.
- Exozymes' Share-based Compensation stood at $107098.0 in 2023, then soared by 196.25% to $317277.0 in 2024, then surged by 113.65% to $677866.0 in 2025.
- Business Quant data shows EXOZ's Share-based Compensation at $677866.0 in Q4 2025, $3.1 million in Q3 2025, and $243778.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | - |
| 10 | Exozymes | 62.92 Mn | 62.92 Mn | - | 961,067.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 961,067.00 |
| Jun 30, 2026 | 961,067.00 |
| Dec 31, 2025 | 677,866.00 |
| Dec 31, 2025 | 677,866.00 |
| Sep 30, 2025 | 3.07 Mn |
| Sep 30, 2025 | 3.07 Mn |
| Jun 30, 2025 | 243,778.00 |
| Jun 30, 2025 | 243,778.00 |
| Mar 31, 2025 | 317,277.00 |
| Mar 31, 2025 | 317,277.00 |
| Dec 31, 2024 | 317,277.00 |
| Dec 31, 2024 | 317,277.00 |
| Sep 30, 2024 | 4.87 Mn |
| Sep 30, 2024 | 4.87 Mn |
| Jun 30, 2024 | 348,275.00 |
| Jun 30, 2024 | 348,275.00 |
| Mar 31, 2024 | 142,810.00 |
| Mar 31, 2024 | 142,810.00 |
| Dec 31, 2023 | 107,098.00 |
| Dec 31, 2023 | 107,098.00 |